— Know what they know.
Not Investment Advice

OBIO

Orchestra BioMed Holdings, Inc.
1W: +1.3% 1M: +10.9% 3M: +3.6% YTD: +6.0% 1Y: +0.0% 3Y: -70.6% 5Y: -63.9%
$4.57
-0.09 (-1.93%)
After Hours: $4.64 (+0.07, +1.64%)
NASDAQ · Healthcare · Biotechnology · $267.4M · Alpha Radar Buy · Power 66
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$267.4M
52W Range2.2-5.424
Volume198,903
Avg Volume216,172
Beta0.59
Dividend
Analyst Ratings
3 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEODavid Hochman
Employees70
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-04
150 Union Square Drive
New Hope, PA 18938
US
215 862 5797
About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Hochman David P P-Purchase 10,000 $4.29 2026-03-13
Aiello Joshua A-Award 70,000 $3.82 2026-02-12
Sherman Darren A-Award 397,000 2026-02-12
Taylor Andrew Lawren A-Award 181,000 2026-02-12
Hochman David P A-Award 504,000 2026-02-12

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms